BioSpace News Archive

With Some Help, Small Canadian Biotech Could Challenge Roche’s Hold in Stroke Treatment

NervGen showed that its proprietary drug NVG-291-R, could repair the nervous system after a stroke in rodents —even when it was given seven days after the episode.

July 29, 2022
·
3 min read
·
Tristan Manalac
Drug Development

A Rare Miss for BMS: Phase III Kidney Cancer Trial Fails to Hit Endpoint

Bristol Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) as an adjuvant treatment for localized renal cell carcinoma (RCC) failed to hit the primary endpoint.

July 29, 2022
·
3 min read
·
Mark Terry
Drug Development

Clinical Catch-Up: Seagen, Astellas, SOTIO & More

InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.

July 29, 2022
·
4 min read
·
Mark Terry
Drug Development

ImmunityBio’s Bladder Cancer Immunotherapy BLA gets FDA Nod

The BLA is for the use of the drug N-803 with BCG to treat patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma with or without Ta or T1 disease.

July 29, 2022
·
3 min read
·
Mark Terry
Employer Resources

How to Handle Layoffs as an Employer

Considering biotech and pharma companies are not immune to the pressures and situations that lead to layoffs, it might be time to learn how to handle layoffs as an employer.

July 29, 2022
·
5 min read
·
Kaley Lefevre
Drug Development

FDA Action Alert: Coherus, Sanofi and Regeneron, Acadia, Myovant and Pfizer

The end of July is busy for the FDA, with Coherus, Sanofi, Acadia, Myovant and Pfizer having PDUFA dates filling the calendar. Here’s a look.

July 29, 2022
·
3 min read
·
Mark Terry
Policy

San Francisco, New York Declare Local Health Emergencies Over Monkeypox

The measures will allow San Francisco and New York to coordinate efforts across different agencies and raise the public’s awareness to curb the spread of monkeypox.

July 29, 2022
·
2 min read
·
Tristan Manalac
Pharm Country

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 29, 2022

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 58,075 shares of its common stock to 25 newly-hired employees, with a grant date of July 26, 2022.

July 29, 2022
·
2 min read
Novogene America Launches a New Single-Cell Lab in San Jose, Based on Chromium Platform Powered by 10x Genomics®

High-throughput sequencing methods mainly bases on Illumina platforms have benefited the entire field of biology for more than a decade.

July 29, 2022
·
2 min read
Genetown

NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants

GreenLight Biosciences has announced a collaboration with the National Institutes of Health to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects.

July 29, 2022
·
3 min read